Cover Image
市場調查報告書

全球動物用疫苗市場:各動物疾病、技術、動物、地區 - 趨勢及預測

Global Veterinary Vaccines Market Segmented by Animal diseases , by Technology, by Animal Type & by Geography - Trends and Forecast (2017 - 2022)

出版商 Mordor Intelligence LLP 商品編碼 319396
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球動物用疫苗市場:各動物疾病、技術、動物、地區 - 趨勢及預測 Global Veterinary Vaccines Market Segmented by Animal diseases , by Technology, by Animal Type & by Geography - Trends and Forecast (2017 - 2022)
出版日期: 2017年01月24日 內容資訊: 英文 190 Pages
簡介

全球動物用疫苗市場預計2014年達120億美元。預期該市場今後也以年複合成長率8.8%擴大,2019年達到190億美元。家畜和寵物的增加、動物的慢性疾病的發病率上升等,促進更良好的動物醫療需求。

本報告提供全球動物用疫苗市場趨勢與未來預測、打入市場的主要企業的競爭環境、市場佔有率、近幾年趨勢與簡介彙整。

第1章 簡介

第2章 市場分析

  • 動物醫療產品市場
  • 動物醫療和人類的醫療

第3章 市場趨勢

  • 推動市場的要素
    • 寵物擁有率的上升
    • 營養的改善
    • 消費者對食品安全的認知提高
    • 家畜生產的增加
    • 人畜共通感染疾病、經由食物傳染疾病
  • 阻礙市場的要素
    • 耕種地和水的不足
    • 耕地相關競爭激烈
    • 成本效益高的生產
  • 波特五力分析

第4章 全球動物用疫苗市場區隔:各動物、疾病

  • 寵物
  • 雞疫苗市場:各疾病
  • 豬疫苗市場:各疾病
  • 馬疫苗市場:各疾病
  • 全球動物用疫苗市場:各技術
    • 類毒素疫苗
    • 重組疫苗
    • 不活化疫苗
    • 弱毒化活病毒疫苗
  • 全球動物用疫苗市場:各地區
    • 北美
    • 歐洲
    • 亞太地區

第5章 競爭環境

  • 市場上主要加入企業
  • 合併、收購
  • 新產品上市
  • 協定、聯合、聯盟

第6章 企業簡介

  • Zoetis animal healthcare
  • Merck
  • Merial (Animal Health Division Of Sanofi)
  • Elanco
  • Bayer healthcare
  • Novartis Animal Health, Inc.
  • Virbac
  • Boehringer Ingelheim

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Description

The global market for veterinary vaccines has been estimated at USD 11,083 million in 2014 and is projected to reach USD 19,021 million by 2020 at a CAGR of 9.42% during the forecast period from 2014 to 2021.

Global Veterinary Vaccines Market- Market Dynamics

Veterinary vaccines help to improve health and welfare of animals, increase production of livestock in a cost-effective manner and prevent transmission of diseases among animals and also to humans. Efficient animal production and better access to high-quality protein dramatically increase meat and egg production and contribute to greater economic outcome. Also, the rapid development of animal vaccines can play an effective role in controlling emerging diseases. Veterinary vaccines comprise only approximately 23% of the global market for animal health products.

Drivers

There are several factors listed in the study that drive the growth of the global veterinary vaccines market. Some of them are:

Technological innovations

Growing awareness of animal health

Increasing investments by government bodies and associations

Increased demand for animal protein, including milk, meat, eggs, and fish

Increased expenditure on health care of companion animals

Restraints

Some of the factors restraining the market growth are:

Rising maintenance costs for storage of vaccines

Increasing adoption of vegetarian food in major economies owing to increasing risk of obesity and other chronic disorders

Persistent economic slowdown

The veterinary vaccines market is segmented on the basis of products, diseases, technologies, and regions. Based on product type, the market is categorized into companion animal vaccines, livestock vaccines, poultry vaccines, porcine vaccines, equine vaccines, aquaculture vaccines and other animal vaccines. The porcine vaccine is the largest sub-segment contributing to a major share of the market, whereas companion animal vaccines are the fastest growing segment due to the increasing prevalence of zoonotic diseases in humans and growing pet population. The technology segment includes live attenuated, inactivated, subunit, conjugate, toxoid, recombinant and DNA vaccines. Live attenuated vaccine technology is the major technology in the veterinary vaccines market. The disease type segment includes Rabies, Brucellosis, Leptospirosis, Influenza, Rift Valley fever, Newcastle disease, Nipah virus infection, Hendra virus infection, Porcine Reproductive and Respiratory Syndrome virus and Japanese encephalitis Q fever.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). The European region is the leading veterinary vaccine market, closely followed by the United States. Middle East, Brazil, Argentina, Mexico, Turkey, China, and India are lucrative markets for veterinary vaccines, owing to the growing demand for livestock, development of new products and favorable government initiatives.

The top 3 players in the veterinary vaccines market are Pfizer, Merck, and Sanofi-Aventis, based on the revenues they generate each year. Pfizer is the market leader in the veterinary vaccines market (by revenue) but Merck is the market leader in livestock vaccines market and Sanofi-Aventis is leading in the companion vaccines market. There have been a few mergers/acquisitions by the key players in the veterinary vaccines market to expand their product portfolio in order to top the global market. Ex: Pfizer acquiring Wyeth, which supposedly is the largest acquisition. The industry players have adopted certain growth strategies to excel in the veterinary vaccines market.

Some of the key players in the market are:

Bayer Healthcare

Boehringer Ingelheim

Ceva Animal Health, Inc.

Elanco

Merck

Merial (Animal Health Division of Sanofi)

Key Deliverables in the Study

Market analysis for the veterinary vaccines market, with region-specific assessments and competition analysis on the global and regional scale.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the veterinary vaccines market on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.

Table of Contents

1. INTRODUCTION

  • 1.1 Market Definition
  • 1.2 Market Recent Trends

2. Market Analysis

  • 2.1 Market Animal Health Products
  • 2.2 Animal medicines vs. human Medicines

3. Market Dynamics

  • 3.1 Market Drivers
    • 3.1.1 Increase in pet ownership
    • 3.1.2 Improved Nutrition
    • 3.1.3 Intensifying consumer focus on food safety
    • 3.1.4 Greater Livestock production
    • 3.1.5 Increasing Zoonotic and Foodborne Diseases
  • 3.2 Market Constraints
    • 3.2.1 Scarcity of arable land and water
    • 3.2.2 Increased competition for cultivated land
    • 3.2.3 Cost-effective production
  • 3.3 Porter's Five Force Analysis
    • 3.3.1 Threat of New Entrant
    • 3.3.2 Internal Rivalry
    • 3.3.3 Buyer bargaining power
    • 3.3.4 Supplier bargaining power
    • 3.3.5 Threat of substitutes

4. Global veterinary vaccine market Segmentation, By Type of Animals, based on diseases

  • 4.1 Companion Animals
    • 4.1.1. 1 Disease mainly transferred by Saliva through Bites and Scratch
    • 4.1.1. 1.1 Capnocytophaga canimorsus
    • 4.1.1. 1.2 Pasteurella multocida
    • 4.1.1. 1.3 Cat scratch disease
    • 4.1.1. 1.4 Rabies
      • 4.1.1.2 Enteric diseases with mainly fecal-oral transmittance
      • 4.1.1.2.1 Salmonellosis
      • 4.1.1.2.2 Campylobacteriosis
      • 4.1.1.2.3 Toxocarosis
      • 4.1.1.2.4 Protozoans
      • 4.1.1.3 Respiratory Tract Diseases
      • 4.1.1.3.1 BRSV
      • 4.1.1.3.2 Enzootic Bronchopneu
      • 4.1.1.3.3 EVPC
      • 4.1.1.3.4 IBR
      • 4.1.1.4 Gastrointestinal Diseases
      • 4.1.1.4.1 BVD/MD
      • 4.1.1.4.2 Leptospirosis
  • 4.2 Poultry Vaccines market, by diseases
    • 4.2.1 Bronchitis
    • 4.2.2 Avian Influenza
    • 4.2.3 Marek's Disease
    • 4.2.4 Newcastle Disease
  • 4.3 Pig vaccines market, by disease
    • 4.3.1 Porcine reproductive disease
    • 4.3.2 Swine Influenza
    • 4.3.3 Swine Pneumonia
  • 4.4 Equine Vaccines market, By Disease
    • 4.4.1 Encephalomyelitis
    • 4.4.2 Rhinopneumonitis
    • 4.4.3 Influenza (Horse Flu)
  • 4.5 Global Veterinary Vaccines Market, By Technology
    • 4.5.1 Toxoid Vaccines
    • 4.5.2 Recombinant Vaccines
    • 4.5.3 Inactivated Vaccines
    • 4.5.4 Live Attenuated Vaccines (LAV)
  • 4.6 Global veterinary vaccines market Segmentation, By Geography
    • 4.6.1 North America
      • 4.6.1.1 US
      • 4.6.1.2 Mexico
      • 4.6.1.3 Canada
    • 4.6.2 Europe
      • 4.6.2.1 France
      • 4.6.2.2 Italy
      • 4.6.2.3 Germany
      • 4.6.2.4 Spain
      • 4.6.2.5 Sweden
      • 4.6.2.6 Rest of Europe
    • 4.6.3 Asia-Pacific
      • 4.6.3.1 India
      • 4.6.3.2 China
      • 4.6.3.3 Japan
      • 4.6.3.4 Rest of Asia-Pacific

5. Competitive landscape

  • 5.1 Major players in the market
  • 5.2 Mergers and acquisitions
  • 5.3 New product launches
  • 5.4 Agreement, Collaborations, and Partnerships
  • 5.5 Recommendations for New players in the market
  • 5.6 Recommendation for Existing players in the market
  • 5.7 Market Share Analysis

6. Company profiles

  • 6.1 Zoetis Animal Healthcare
    • 6.1.1 Financial Overview
    • 6.1.2 Business overview
    • 6.1.3 Business strategies
  • 6.2 Merck
    • 6.2.1 Financial Overview
    • 6.2.2 Business overview
    • 6.2.3 Business strategies

6. 3 Merial (Animal Health Division of Sanofi)

    • 6.3.1 Financial Overview
    • 6.3.2 Business overview
    • 6.3.3 Business strategies
  • 6.4 Elanco
    • 6.4.1 Financial Overview
    • 6.4.2 Business overview
    • 6.4.3 Business strategies
  • 6.5 Bayer healthcare
    • 6.5.1 Financial Overview
    • 6.5.2 Business overview
    • 6.5.3 Business strategies
  • 6.6 Ceva Animal Health, Inc.
    • 6.6.1 Financial Overview
    • 6.6.2 Business overview
    • 6.6.3 Business strategies
  • 6.7 Virbac
    • 6.7.1 Financial Overview
    • 6.7.2 Business overview
    • 6.7.3 Business strategies
  • 6.8 Boehringer Ingelheim
    • 6.8.1 Financial Overview
    • 6.8.2 Business overview
    • 6.8.3 Business strategies

7. Appendix

  • 7.1. Abbreviations
  • 7.2. Sources
  • 7.3. Bibliography
  • 7.4. Disclaimer
Back to Top